Reaction profile

The FDA adverse-event record for skin hyperplasia

15 FDA reports name skin hyperplasia, a lower-volume reaction in the CVM extract (VeDDRA 2986). Plate stamps and neighbourhood peers follow.

#2315 of 2,481
by report volume (all reactions)
15
reports citing this reaction
13.3%
death-coded share
Dog
most-affected species

Release-over-release change

What changed in the latest FDA data snapshot

PlainBreed reconstructed the prior snapshot from dated openFDA partitions through 2025 Q4, then compared it with the 2026-07-27 openFDA export. Skin hyperplasia has 15 reports now versus 14 in that prior snapshot: 1 more (7.1%).

Report change
+1
Death-coded reports
+0
Death-coded share
−1.0 pts

This compares reported-event counts in two source snapshots. It does not establish a change in real-world risk, product safety, or disease incidence.

Subscribe to Skin hyperplasia changes

FDA AER · VeDDRA plate

Code 2986 VOL-TRACE

VOL-TRACE · DEATH-ELEV · BOTTOM-DECILE · PHOTO-FINISH · SPECIES-DOG · DRUG-LEAD · DESK-WIDE · BOOK-FULL

  • VOL-TRACE 15 reports
  • DEATH-ELEV 13.3%
  • BOTTOM-DECILE #2315/2481
  • PHOTO-FINISH Abomasal ulcer
  • SPECIES-DOG Dog · 10
  • DRUG-LEAD Frunevetmab · 3
  • DESK-WIDE 12 breeds
  • BOOK-FULL 8/8 fields

Nearest volume peer: Abomasal ulcer (±0 reports)

Instrument codes from this reaction’s FDA CVM adverse-event extract: volume band, death-coded share, corpus rank, photo-finish peer, lead species, lead drug, breed desk, and book completeness. Not a clinical diagnosis.

Lower-volume neighbourhood around Skin hyperplasia

Lower-third volume poles plus nearest peers, not a full reaction corpus board reprint.

Vomiting · highest174348Abomasal ulcer · near15Burning sensation of… · near15Chronic hepatitis · near15Conjunctival haemorrh… · near15Skin hyperplasia · this reac…15Urinary tract neoplas… · low…10
FDA AER report volume · neighbourhood around Skin hyperplasia

What the FDA AER plate says about Skin hyperplasia

Signature read: 15 reports place Skin hyperplasia in the lower third of FDA AER volume (#2315 of 2,481). Report volume is lower-third scale: 15 named reports in the openFDA extract. 2 of 15 reports were death-coded (13.3% of named reports, not a population mortality rate). Nearest volume peer: Abomasal ulcer (±0 reports). Lead species Dog (10). Lead co-reported drug Frunevetmab (3).

Read these counts as reporting volume, not risk: per our methodology, Lead co-reported drug Frunevetmab appears in filings alongside this reaction; that is association, not causation. Browse the full reactions index or the about page for how PlainBreed frames FDA CVM extracts.

Species Most Affected

Dog 10
Cat 5

Breeds Most Affected

Domestic Shorthair 3
Retriever - Labrador 2
Coonhound (unspecified) 1
Persian 1
Retriever - Golden 1
Shepherd Dog (unspecified) 1
Domestic Longhair 1
Shepherd Dog - German 1
Doberman Pinscher 1
Terrier - Irish Soft-coated Wheaten 1

Associated Drugs

Frunevetmab 3
Oclacitinib Maleate 3
Enrofloxacin 2
Bedinvetmab 2
Rabies Vaccine 2
Anti-Il31 Mab Mcs Lot #1283563 2
Rabacfosadine 1
Cyclosporine 1
Nystatin + Neomycin Sulfate + Thiostrepton + Triamcinolone Acetonide 1
Dexamethasone, Baytril, Antifungal Concoction For The Ear 1
Mometamax 1
Robenacoxib 1
Rabies Vaccine, Killed Virus 1
Feline Rhinotracheitis Calici Panleukopenia Vaccine, Killed Virus 1
Afoxolaner 150Mg / Moxidectin 720Mcg / Pyrantel 300Mg Chewable Tablet 1
Selamectin 1
Fluralaner 13.64% 12-Week Chew 1
Carprofen 1
Dasequin 1
Gabapentin 1

What to do with this reaction

A report does not prove a drug caused the reaction; consult a veterinarian before acting on this data.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

openFDA Animal & Veterinary Adverse Events (FDA CVM) for Skin hyperplasia (#2315 of 2,481 by report volume); death-coded 13.3%. PlainBreed reaction plate · report volume stamp 15 · vintage 2025.

Informational only. FDA adverse-event reports are voluntary and do not prove causation; consult a veterinarian before acting on them. Verify with FDA CVM →